1. Japan Stocks

  2. •

    Process industries

  3. •

    Textiles
Gunze Limited

Gunze Limited

23.20
EUR
+0.20
(+0.87%)
Nov 05Next Earn
Gunze Limited
STU:GUN
(Stuttgart Stock Exchange)

Recent

price

23.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
3,436.09
3,542.32
3,454.45
3,715.58
3,683.82
3,677.19
3,652.63
3,814.98
3,883.26
3,917.55
3,481.5
3,572.24
3,949.77
3,915.93
4,142.55
4,071.58
- -
Revenue per Share
46.16
14.8
-30.3
65.43
83.89
-31.93
82.96
94.64
112.79
122.49
60.45
84.45
130.69
150.55
189.7
15.83
- -
Basic EPS, GAAP
129.78
-36.74
322.11
358.79
248.21
313.03
369.92
244.53
317.13
382.18
242
263.07
52.09
306.74
349.61
537.13
- -
Free Cash Flow per Basic Share
37.83
37.34
37.32
37.33
37.32
38.07
42.34
37.98
45.48
55.53
57.33
58.25
69.95
73.58
76.8
196.15
- -
Dividend per Share
2,917.11
2,851.04
2,813.73
2,939.81
3,028.25
2,818.82
2,900.1
3,049.93
3,036.68
3,035.82
3,214.23
3,271.43
3,398.5
3,559.98
3,670.47
3,568.36
- -
Book Value per Share
2,860.39
2,801.05
2,770.09
2,901.5
2,996.68
2,783.49
2,848.89
3,000.19
2,977.42
2,985.84
3,168.69
3,232.56
3,356.1
3,502.19
3,615.5
3,524.17
- -
Tangible Book Value per Share
39
39
38
38
38
38
37
37
36
36
36
35
34
34
33
32
32
Basic Weighted Avg Shares
133,705
136,621
132,373
142,425
141,172
138,324
136,579
140,521
140,706
140,311
123,649
124,314
136,030
132,885
137,117
130,918
- -
Sales/Revenue/Turnover
2.31
0.75
1.29
3.07
2.19
2.65
3.08
4.44
4.75
4.81
3.78
3.93
4.27
5.1
5.78
3.73
- -
Operating Margin (%)
7,898
8,171
7,587
6,288
6,950
6,604
6,861
6,528
6,650
6,523
6,288
6,191
5,893
6,208
6,867
7,305
- -
Depreciation Expense
1,796
571
-1,161
2,508
3,215
-1,201
3,102
3,486
4,087
4,387
2,147
2,939
4,501
5,109
6,279
509
- -
Net Income, GAAP
40.22
82.25
- -
41.56
45.33
- -
52.82
31.73
32.61
23.73
32.57
45.87
29.11
- -
30.36
48.95
- -
Effective Tax Rate (%)
1.34
0.42
-0.88
1.76
2.28
-0.87
2.27
2.48
2.9
3.13
1.74
2.36
3.31
3.84
4.58
0.39
- -
Profit Margin (%)
32,465
32,048
37,368
41,001
42,181
33,172
29,259
34,009
36,361
40,110
41,227
47,978
53,528
55,906
53,423
41,630
- -
Working Capital
5,175
7,678
11,647
13,333
12,889
14,355
8,562
9,912
10,972
11,973
4,581
2,317
8,638
8,230
5,668
5,261
- -
LT Debt
113,345
110,196
108,745
114,181
117,358
106,639
108,353
112,129
111,066
109,139
115,176
114,787
117,689
120,463
120,977
113,744
- -
Total Equity
1.34
0.13
- -
1.81
1.17
- -
1.44
3.06
3.22
3.76
2.35
2.03
3.15
- -
4.2
1.92
- -
Return on Invested Capital (%)
1.38
0.54
- -
1.7
2.4
- -
3.44
2.54
2.94
3.27
1.59
2.28
3.58
- -
4.82
0.37
- -
Return on Capital (%)
1.56
0.51
-1.07
2.27
2.81
-1.08
2.9
3.17
3.7
4.03
1.94
2.59
3.93
4.35
5.28
0.44
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
9,956
9,140
- -
LT Borrowings
5,649
5,261
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
31
31
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
74,714
69,266
- -
Cash, Cash Equivalents & STI
9,380
9,936
- -
Accounts Receivable, Net
24,366
22,560
- -
Inventories
37,411
33,110
- -
Total Current Liabilities
30,675
27,636
- -
Payables & Accruals
- -
- -
- -
ST Debt
9,956
9,140
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.69%
-0.2%
-5.98%
Free Cash Flow
45.88%
93.35%
49.25%
Net Income, GAAP
-33.78%
6.91%
-91.89%
Sales/Revenue/Turnover
-0.41%
1.26%
-4.52%
Total Cash Common Dividend
21.17%
34.39%
148.11%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
137,117
2026
- -
- -
- -
- -
130,918
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
189.7
2026
- -
- -
- -
- -
15.83
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
76.8
2026
- -
- -
- -
- -
196.15
2027
- -
- -
- -
- -
- -
Similar Companies
Sasa Polyester Sanayi A.S. (BIST:SASA)
WF Holding Limited (NASDAQ:WFF)
Raymond Limited (NSE:RAYMOND)
Aksa Akrilik Kimya Sanayii A.S. (BIST:AKSA)
Filatex India Ltd (NSE:FILATEX)
Indo Count Industries Limited (NSE:ICIL)
Business
Gunze Limited is a Japan-based diversified manufacturer engaged in apparel, functional solutions, medical materials, and lifestyle creations businesses primarily in Japan with international operations. Founded in 1896 and headquartered in Osaka with registered offices in Ayabe, Kyoto, and additional facilities in Tokyo, the company operates through three main segments. The Apparel segment manufactures and sells innerwear, legwear, lifestyle wear, threads, and accessories under brands including BODY WILD, KIREILABO, YG, SEEK, Kaiteki Kobo, Tuché, Sai, COOLMAGIC, HOTMAGIC, MediCure, SABRINA, and KAIMIN NAVI; the Functional Solutions segment produces plastic films such as shrink films, flexible multilayer sheets, OPP films, and nylon films, engineering plastics including fluoro resin heat-shrinkable tubes, thin-walled tubes, fiber products, and seamless belts, mechatronics equipment for packaging, printing, pharmaceuticals, cosmetics, dairy, beverages, and food products, and electronic components like touch screen technologies; the Medical Materials segment offers bioabsorbable surgical suture threads, bone fixation devices, artificial dura mater, artificial dermis, adhesion barrier sheets, absorbable reinforcement felt, and medical stockings; and the Lifestyle Creations segment handles commercial facility development, landscaping, greening, sports clubs, spas, real estate leasing for shopping complexes, housing, and offices, plant materials sales, and energy engineering including solar power systems and thermal insulation. In recent developments, Gunze completed the separation of its medical business into an independent segment in fiscal 2023 following the 2022 merger of sales subsidiaries into Gunze Medical Limited and the integration of R&D, pharmaceutical affairs, and management functions dedicated to medical devices; the company launched VISION 2030 Stage 2 in May 2025, a three-year medium-term plan targeting sustainable growth through core business expansion, high-profitability proprietary medical products, area-specific strategies in wound care and thoracic/abdominal surgery, new product development, and investments in production facilities such as a new medical R&D plant and expanded engineering plastics plant at Konan by March 2025, alongside full-scale operation of its Circular Factory for plastic films recycling; additionally, Gunze announced an equity buyback of 1.4 million shares representing 4.31% for ¥5 billion in November 2025 and reported consolidated net sales of ¥137.1 billion for fiscal year ended March 31, 2025, with ongoing share consolidation efforts.